21P Peripheral pre-existing T cell immunity as predictive biomarker in cancer immunotherapy for NSCLC patients. (December 2022) - Xagara, A.; Fortis, S.; Goulielmaki, M.; Koinis, F.; Chantzara, E.; Samaras, I.; Papadopoulos, V.N.; Georgoulias, V.; Baxevanis, C.N.; Kotsakis, A.